Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Niraparib versus temozolomide in newly diagnosed MGMT-unmethylated glioblastoma
NL-OMON61119Phase 3Active, not recruiting
- Sponsor
- NeuroTrials
- Start
- Mar 2025
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of niraparib, temozolomide in glioblastoma (GBM), sponsored by NeuroTrials. Started Mar 2025; status: active, not recruiting.
02
Drugs
niraparibtemozolomide
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NL-OMON61119.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61119.